C Diff Drug Development

Cambridge, MA, July 01, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (the “Company”) today announced that members of our scientific...

Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that using specimens from a Phase 1 healthy volunteer trial and a novel analysis technique, beneficial changes potentially predictive of lower risk of CDI (Clostridioides difficile Infection) recurrence were associated with ibezapolstat compared to vancomycin. These results were presente

Companies Agree to Jointly Commercialize SER-109 Investigational Microbiome Therapeutic to Treat Recurrent C. Difficile Infection, Leading the Way for Entirely New Treatment Modality Deal calls for more than $500 million in upfront and contingent milestone payments Seres Therapeutics to conduct a conference call at 8:30 a.m. ET

New data suggest a microbiota-based therapy can reduce C diff recurrence in patients where donor microbiota and patient microbiota successfully converge.

Seres Therapeutics and Nestlé Health Science have announced a decision to team up for the joint commercialization of Seres’s investigational oral microbiome treatment for recurrent Clostridioides difficile infections.

Nestlé Health Science will help Seres Therapeutics bring its microbiome drug candidate to the U.S. market, per a new deal announced Thursday.

After a rough couple of years, things are looking up for Seres Therapeutics. The microbiome company’s partner Nestlé Health Sciences is handing over $175 million upfront to help market its lead microbiome treatment in North America.

ADELAIDE, South Australia, June 30, 2021--Australian biotech company BiomeBank submits for Market Authorisation of their microbial product for Clostridioides difficile and Ulcerative Colitis.

Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced additional results from a Phase 1 study in healthy volunteers of VE202, the Company’s 16-strain live biotherapeutic product (LBP) candidate for inflammatory bowel disease (IBD).

/PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed...

C. difficile is a major cause of antibiotic-associated gastrointestinal infections. Two C. difficile exotoxins (TcdA and TcdB) are major virulence factors associated with these infections, and chondroitin sulfate proteoglycan 4 (CSPG4) is a potential receptor for TcdB, but its pathophysiological rel …

Investigators found that the therapeutic mechanism for bezlotoxumab, the only FDA-approved anti-TcdB antibody, is sensitive to escaping mutations in some bacterial strains.

Antibiotic choice impacts C. difficile shedding and hospital contamination, study finds - Healio https://t.co/HqporFvhnT #cdi #cdiff— Dave Roberts (@CDifficile1) June 25, 2021

We are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs.

Strain typing data is not often available to assess whether recurrence is due to CDI relapse or reinfection.

clinical trials for c diff symptoms & prevention

C. difficile is a major cause of antibiotic-associated gastrointestinal infections. Two C. difficile exotoxins (TcdA and TcdB) are major virulence factors associated with these infections, and chondroitin sulfate proteoglycan 4 (CSPG4) is a potential receptor for TcdB, but its pathophysiological rel …

A new study paves the way for the development of next generation therapeutics for the prevention and treatment of Clostridioides difficile infection (CDI), the most frequent cause of healthcare-acquired ...

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) infections.

Seres expects to move forward with plans for SER-109 as a novel treatment for CDI.

Crestone, Inc. enrolls first patient in Phase 2 clinical trial for novel antibiotic CRS3123 to treat C. difficile infections

In a video exclusive, Paul Feuerstadt, MD, FACG, AGAF, Yale University School of Medicine, tells Healio Gastroenterology about new study data regarding investigational biotherapeutic RBX2660 for the treatment of Clostridioides difficile.“RBX2660 provides us with a beacon of hope that the FDA will approve a product like this and that, what we saw in March and April 2020, will never happen

Seres expects to move forward with plans for SER-109 as a novel treatment for CDI.

A new study published in Nature Communications demonstrates that a consortium of bacteria designed to complement missing or underrepresented functions in the imbalanced microbiome of inflammatory bowel ...